Mutations in the presenilin 1 gene (PS1) account for the majority of early onset, familial, autosomal dominant forms of Alzheimer's disease (AD), whereas its role in other late onset forms of AD remains unclear. A −48 C/T polymorphism in the PS1 promoter has been associated with an increased genetic risk in early onset complex AD and moreover has been shown to influence the expression of the PS1 gene. This raises the possibility that previous conflicting findings from association studies with homozygosity for the PS1 intron 8 polymorphism might be the result of linkage disequilibrium with the -48 CC genotype. Here we provide further evidence of increased risk of AD associated with homozygosity for the −48 CC genotype (odds ratio=1.6). We also report a phenotypic correlation with A 40 , A 42(43) , and total A load in AD brains. The −48 CC genotype was associated with 47% greater total A load (p<0.003) compared to CT + TT genotype bearers. These results suggest that the -48 C/T polymorphism in the PS1 promoter may increase the risk of AD, perhaps by altering PS1 gene expression and thereby influencing A load. (J Med Genet 2001;38:353-355) Keywords: Alzheimer; presenilin; promoter; polymorphism Epidemiological and molecular studies suggest that multiple genes and environmental factors underlie the aetiology of AD. To date, four genes have been shown to play a role in AD. The apolipoprotein E (APOE) gene is recognised as a major risk factor for complex forms of AD (that is, non mendelian patterns of inheritance), while pathogenic mutations in the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) genes are responsible for some rare, early onset, autosomal dominant forms, with 18-50% of cases being caused by mutations in the PS1 gene.
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The apolipoprotein E (APOE) gene is recognised as a major risk factor for complex forms of AD (that is, non mendelian patterns of inheritance), while pathogenic mutations in the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) genes are responsible for some rare, early onset, autosomal dominant forms, with 18-50% of cases being caused by mutations in the PS1 gene. 2 In vitro and in vivo studies show that pathogenic mutations in PS1 favour A peptide production, particularly A 42(43) , 3 the species suspected to initiate the formation of amyloid plaques. 4 This observation is of particular relevance given the greater A 42(43) deposition in the brains of patients bearing PS1 mutations, 5 greater than found in complex forms of AD.
The role of genetic variations of PS1 in complex forms of AD is unclear. Despite our original observation of an association between a single nucleotide polymorphism (SNP) in intron 8 of PS1 and AD, 6 these data have not always been replicated and no functional role has been ascribed to this polymorphism. 7 It has been suggested that the association with the intron 8 polymorphism might be spurious or that the disease associated allele might be in linkage disequilibrium with a functional variant elsewhere in the gene. The -48 C/T polymorphism in the PS1 promoter is a possible candidate and has recently been associated with an increased risk of early onset AD (EOAD). 8 9 We therefore tested the impact of this polymorphism in our UK white AD cases and controls and have hypothesised that because the PS1 pathogenic mutations aVect APP metabolism, this polymorphism might also modulate A load in human AD brains.
Methods

STUDY POPULATION
All AD cases were white (n=287, mean age=67.1 (SD 13.0) years, mean age at onset=63.1 (SD 10.4) years, 49% males), ascertained from two UK centres, the central belt of Scotland (n=164, 25% had been confirmed as definite AD; in this definite AD population, only one case had early onset AD) and Greater Manchester (n=123, all of which were probable AD cases). Diagnoses of definite or probable AD were established according to DSM-III-R and NINDCS-ADRDA criteria. Early (EOAD) and late onset AD (LOAD) were defined as cases with onset before 65 years of age or >65 years of age (EOAD n=177, LOAD n=110). The proportion of AD cases with a family history was 20%. The white controls were collected from the same geographical areas as the AD patients and were defined as subjects without DSM-III-R dementia criteria and with full integrity of their cognitive functions (n=482, mean age=62.5 (SD 14.4) years, 42% males). Ethical approval for the study and informed consent was obtained from all participants and their relatives and data were anonymised to ensure subject confidentiality.
BRAIN SAMPLES
Brains from a further 99 cases of definite AD (mean age at onset=65.8 (SD 10.0) years, mean age at death=74.3 (SD 9.1) years, 49% males) were collected from the Greater Manchester area. DNA was extracted from the frozen brain tissues of these cases by standard methods. The proportion of tissue area occupied by A 40 , A 42(43) , and total A (A 40 +A 42(43) ) was quantified in immunohistochemically stained sections from Brodmann areas 8/9 of the frontal cortex, as previously reported. 4 GENOTYPING APOE and −48 C/T genotypes were determined as previously reported. 9 10 The −48 TT and CT genotypes were replicated to confirm the complete digestion of the C allele fragment.
STATISTICAL ANALYSIS
Univariate analyses were performed by Pearson's 2 test. In the multivariate analysis, we tested the hypothesis that possession of the -48 CC genotype increases the risk of AD (that is, −48 CC versus −48 CT + TT genotypes). 8 9 The eVect of the CC variant on risk for AD was assessed using a multiple logistic regression model adjusted for age and gender. The amyloid load for -48 CC bearers was compared with −48 CT + TT bearers using the Wilcoxon non-parametric test.
Results
The distributions of the −48 C/T alleles and genotypes for AD and control subjects are shown in table 1. The frequency of the −48 T allele in the control population was 11%, similar to that previously reported in a Dutch population. 9 We observed a significant diVerence for both allele and genotype distributions between the AD and control populations (p=0.01 and p=0.03, respectively), the −48 CC genotype being associated with an increased risk of developing AD (OR=1.55, 95% CI 1.03-2.35, p=0.04). Similar trends were observed in the Scottish and Manchester populations (respectively, OR=1.31, 95% CI 0.81-2.13, p=0.27 and OR=1.75, 95% CI 0.82-3.69, p=0.14) (table 1). The eVect of this polymorphism was similar whether familial or sporadic disease (in the population without a family history, OR=1.63, 95% CI 1.04-2.57, p=0.034) or whether definite or probable AD cases were analysed separately. This eVect appears to be independent of the APOE 4 allele (OR=1.68, 95% CI 1.09-2.59, p=0.02, adjusted for the presence of at least one 4 allele). No significant interaction with PS1 was detected with age or sex. We also observed a stronger eVect of -48 CC genotype in EOAD cases compared to LOAD and age matched control cases; however, they were not significantly diVerent (OR=1.56, 95% CI 0.91-2.75, p=0.11 and 1.27, 95% CI 0.72-2.82, p=0.31, respectively) (table 2).
We next tested the hypothesis that the −48 C/T polymorphism may be associated with A peptide load in brains from AD patients. We observed that all three measures of A load (A 40 , A 42(43) , and total A ) were significantly increased in -48 CC bearers (table 3) . Subjects bearing the −48 CC genotype presented a 100% and 37% increase in A 40 (p=0.007) and A 42(43) (p=0.01) load, respectively, leading to a 47% (p=0.003) increase in total A load. This increased load appears to be independent of the APOE 4 allele (table 4). We found no relationship between -48 CC genotype and the age of onset of disease in the Manchester cohort of brains, but we did detect a trend towards a shorter duration of illness (CC=7.8 (SD 3.7) years, CT and TT=9.5 (SD 3.1) years, p=0.067 with Wilcoxon non-parametric test).
Discussion
In this study we provide further evidence of an association in our UK population between AD and the -48 C/T polymorphism in the PS1 gene promoter. We detected an overall in- Values are % area occupied in Brodmann area 8/9 of the frontal cortex (mean (SD)). Values are % area occupied in regions 8 and 9 (mean (SD)).
creased frequency of the -48 CC genotype in AD cases (OR=1.6) whereas a slightly stronger eVect had been reported in a Dutch EOAD sample (OR=2.6). 9 We also found a trend towards a stronger eVect in EOAD cases in our population. Interestingly, in a second Dutch LOAD cohort, no association with the -48 C/T polymorphism was detected. 10 Thus, we could speculate that the -48 C/T polymorphism may have a greater impact in earlier onset forms of the disease, as do the dominant AD mutations in the PS1 gene.
Considerable research eVort has been directed towards understanding the function of PS1 protein. Evidence suggests that it plays a role in cell traYcking 11 and apoptosis 12 and chromosomal segregation.
13 PS1 has been implicated in the -secretase activity that generates the carboxy-terminus of A peptides.
14 Because mutations in PS1 in familial AD are directly implicated in APP metabolism and production of A , we hypothesised that variations of PS1 expression because of polymorphisms in the promoter may similarly influence the production of A . Indeed, A peptide production can be reduced after inhibition of PS1 expression in cultured cells. 15 In this present study, we have reported that the -48 CC genotype correlates with increased A deposition, supporting the view that genetic variants in the PS1 promoter increase the risk of developing AD by modulating PS1 expression and consequently APP metabolism. Mutations in the PS1 gene increase the total amount of A secreted and deposited through selectively influencing the activity of -secretase in favour of the production of A 42(43) . 16 We have shown here that the -48 C/T polymorphism is associated with brain increases in both A 40 and A 42(43) , implying that its modulatory eVect on PS1 activity is unselective, at least as far as the composition of the C-terminal A peptides that are produced is concerned. Hence, while the -48 C/T polymorphism leads to increased deposition of A , this might be achieved by driving more APP per se through the catabolic cascade rather than, as is the case with the PS1 mutants, by facilitating the preferential production of the more highly aggregatable species A 42(43) .
Our epidemiological studies and those of others 9 are supported by genotype-phenotype correlations that suggest that the -48 C/T polymorphism might exert a functional role by influencing PS1 gene expression 17 and A load, as described here. Other polymorphisms have been reported in the PS1 promoter, which appear to be in linkage disequilibrium with the −48 C/T polymorphism. 9 Further epidemiological and functional studies are required to determine which of these modifies the risk of AD. These data emphasise the potential importance of control of gene expression in the pathogenesis of AD. Genetic variability in the APP promoter has been suggested to increase the risk of late onset AD, 18 and we have recently reported that polymorphisms in the APOE promoter modulate risk for AD. 19 20 In conclusion, our findings are consistent with the established eVects of PS1 mutations on APP metabolism, suggesting that variations in the level of PS1 expression per se may have an impact upon AD pathology.
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